"Poland Pharmaceuticals & Healthcare Report Q4 2012" Now Available at Fast Market Research
BMI View: Despite a downgrade to our 2012 growth projections for Poland's pharmaceutical market and a less bullish long-term view on the Polish zloty against the US dollar and the euro, we continue to have a positive view on the Polish drug market. Despite the short-term challenges, the market remains attractive over the medium term, and as one of Central Europe's larger markets, the combination of positive demographics and economic growth will be a driver of growth. Over a longer...
View full press release